ES2444772T3
(es)
*
|
2001-02-24 |
2014-02-26 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Derivados de xantina, su preparación y uso como medicamentos
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
CN1894234A
(zh)
|
2003-03-25 |
2007-01-10 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
ZA200508439B
(en)
|
2003-05-05 |
2007-03-28 |
Probiodrug Ag |
Medical use of inhibitors of glutaminyl and glutamate cyclases
|
JP2007511467A
(ja)
|
2003-05-14 |
2007-05-10 |
タケダ サン ディエゴ インコーポレイテッド |
ジペプチジルペプチダーゼインヒビター
|
PT1638970E
(pt)
*
|
2003-06-20 |
2010-12-13 |
Hoffmann La Roche |
Derivados de pirid(2,1-a)isoquinolina como inibidores de dpp-iv
|
NZ543863A
(en)
*
|
2003-06-20 |
2009-05-31 |
Hoffmann La Roche |
Hexahydropyridoisoquinolines as DPP-IV inhibitors
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7470700B2
(en)
*
|
2003-08-13 |
2008-12-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
JP2007505121A
(ja)
|
2003-09-08 |
2007-03-08 |
武田薬品工業株式会社 |
ジペプチジルぺプチダーゼ阻害剤
|
US20050065144A1
(en)
*
|
2003-09-08 |
2005-03-24 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
US20050137142A1
(en)
|
2003-11-03 |
2005-06-23 |
Probiodrug Ag |
Combinations useful for the treatment of neuronal disorders
|
AU2005210004B2
(en)
|
2004-02-05 |
2010-10-28 |
Probiodrug Ag |
Novel inhibitors of glutaminyl cyclase
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
BRPI0418639B8
(pt)
|
2004-03-15 |
2021-05-25 |
Takeda Pharmaceutical |
compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos
|
EP1734963A4
(fr)
|
2004-04-02 |
2008-06-18 |
Merck & Co Inc |
Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques
|
EP1753730A1
(fr)
|
2004-06-04 |
2007-02-21 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de la dipeptidyl peptidase
|
WO2006019965A2
(fr)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Inhibiteurs de la dipeptidyl peptidase
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
AU2005311511A1
(en)
*
|
2004-11-30 |
2006-06-08 |
F. Hoffmann-La Roche Ag |
Substituted benzoquinolizines as DPP-IV inhibitors for the treatment of diabetes
|
JP2008524276A
(ja)
*
|
2004-12-20 |
2008-07-10 |
エフ.ホフマン−ラ ロシュ アーゲー |
4−アミノピペリジン誘導体
|
JP2008524331A
(ja)
|
2004-12-21 |
2008-07-10 |
武田薬品工業株式会社 |
ジペプチジルペプチダーゼ阻害剤
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
DE602006017997D1
(de)
*
|
2005-04-26 |
2010-12-16 |
Mitsubishi Tanabe Pharma Corp |
Prophylaktisches/therapeutisches mittel für abweichungen im fettstoffwechsel
|
MY152185A
(en)
|
2005-06-10 |
2014-08-29 |
Novartis Ag |
Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
BRPI0614732A2
(pt)
*
|
2005-08-11 |
2011-04-12 |
Hoffmann La Roche |
composição farmacêutica que compreende um inibidor de dpp-iv, uso de um inibidor de dpp-iv e método para o tratamento de enfermidades associadas com nìveis de glicose sanguìnea elevados
|
US20070060530A1
(en)
|
2005-09-14 |
2007-03-15 |
Christopher Ronald J |
Administration of dipeptidyl peptidase inhibitors
|
BRPI0616077B8
(pt)
*
|
2005-09-14 |
2021-05-25 |
Takeda Pharmaceuticals Co |
composição farmacêutica formulada em uma dose única, kit, artigo de manufatura, uso da composição farmacêutica e uso de um ou mais compostos antidiabéticos
|
CN102675221A
(zh)
|
2005-09-16 |
2012-09-19 |
武田药品工业株式会社 |
用于制备嘧啶二酮衍生物的方法中的中间体
|
TW200745080A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
|
TW200745079A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
WO2007112347A1
(fr)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de la dipeptidyl peptidase
|
EP1999108A1
(fr)
*
|
2006-03-28 |
2008-12-10 |
Takeda Pharmaceutical Company Limited |
Préparation de dichlorhydrate de (r)-3-aminopipéridine
|
PE20071221A1
(es)
*
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
KR101281962B1
(ko)
|
2006-04-11 |
2013-07-08 |
아레나 파마슈티칼스, 인크. |
특정 개체에게서 골 질량을 증가시키는 데에 유용한 화합물을 확인하기 위해 gpr119 수용체를 사용하는 방법
|
BRPI0709984A2
(pt)
|
2006-04-12 |
2011-08-02 |
Probiodrug Ag |
inibidores de enzima
|
UA97244C2
(en)
|
2006-05-04 |
2012-01-25 |
Берингер Ингельхайм Интернациональ Гмбх |
Polymorphs of 1-((4-methyfquinazolin-2-yl)methyl)-3-methyl-7- (2-butyn-1-yl)-8-(3-(r)-aminopiperidin-l-yl)xanthine
|
EP1852108A1
(fr)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Compositions d'inhibiteurs de la DPP IV
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
JP5230613B2
(ja)
|
2006-05-23 |
2013-07-10 |
テラコス・インコーポレイテッド |
グルコース輸送体阻害剤およびその使用方法
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
EP2069343A2
(fr)
*
|
2006-09-15 |
2009-06-17 |
F. Hoffmann-Roche AG |
Méthode de préparation de dérivés de pyrido[2,1-a]isoquinoline par hydrogénation asymétrique catalytique d'une énamine
|
JP5235018B2
(ja)
*
|
2006-09-15 |
2013-07-10 |
エフ.ホフマン−ラ ロシュ アーゲー |
エナミンの光学分割を含むピリド[2,1−a]イソキノリン誘導体の製造方法
|
JP5379692B2
(ja)
|
2006-11-09 |
2013-12-25 |
プロビオドルグ エージー |
潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体
|
TW200838536A
(en)
*
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
JP5523107B2
(ja)
|
2006-11-30 |
2014-06-18 |
プロビオドルグ エージー |
グルタミニルシクラーゼの新規阻害剤
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
ES2533484T3
(es)
|
2007-04-18 |
2015-04-10 |
Probiodrug Ag |
Derivados de tiourea como inhibidores de la glutaminil ciclasa
|
ES2733348T3
(es)
*
|
2007-08-17 |
2019-11-28 |
Boehringer Ingelheim Int |
Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
|
KR101107425B1
(ko)
|
2007-08-23 |
2012-01-19 |
테라코스, 인코포레이티드 |
벤질벤젠 유도체 및 사용 방법
|
US20090163718A1
(en)
*
|
2007-12-19 |
2009-06-25 |
Stefan Abrecht |
PROCESS FOR THE PREPARATION OF PYRIDO[2,1-a] ISOQUINOLINE DERIVATIVES
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
EP2146210A1
(fr)
*
|
2008-04-07 |
2010-01-20 |
Arena Pharmaceuticals, Inc. |
Procédés d'utilisation du récepteur couplé aux protéines A G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement d'états modulés par PYY
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
WO2010009243A1
(fr)
|
2008-07-15 |
2010-01-21 |
Theracos, Inc. |
Dérivés de benzylbenzène deutérés et procédés d’utilisation
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
KR101657960B1
(ko)
*
|
2008-08-15 |
2016-09-20 |
베링거 인겔하임 인터내셔날 게엠베하 |
Fab-관련 질환의 치료에 사용하기 위한 푸린 유도체
|
AU2009290911A1
(en)
|
2008-09-10 |
2010-03-18 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
WO2010047982A1
(fr)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques
|
JP5557845B2
(ja)
|
2008-10-31 |
2014-07-23 |
メルク・シャープ・アンド・ドーム・コーポレーション |
糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
|
CN102256976A
(zh)
|
2008-12-23 |
2011-11-23 |
贝林格尔.英格海姆国际有限公司 |
有机化合物的盐形式
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
DK2475428T3
(en)
|
2009-09-11 |
2015-09-28 |
Probiodrug Ag |
Heterocyclic derivatives as glutaminylcyklaseinhibitorer
|
KR20190071840A
(ko)
|
2009-11-27 |
2019-06-24 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
AU2011218830B2
(en)
|
2010-02-25 |
2014-07-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
US9181233B2
(en)
|
2010-03-03 |
2015-11-10 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
BR112012022478B1
(pt)
|
2010-03-10 |
2021-09-21 |
Probiodrug Ag |
Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
|
EP2556056A1
(fr)
|
2010-04-06 |
2013-02-13 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur de gpr119 et traitement de troubles associés
|
EP2560953B1
(fr)
|
2010-04-21 |
2016-01-06 |
Probiodrug AG |
Inhibiteurs de glutaminyl cyclase
|
ES2935300T3
(es)
|
2010-05-05 |
2023-03-03 |
Boehringer Ingelheim Int |
Combiterapia
|
WO2011153712A1
(fr)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène
|
CN106975074A
(zh)
|
2010-06-24 |
2017-07-25 |
勃林格殷格翰国际有限公司 |
糖尿病治疗
|
WO2012018950A1
(fr)
|
2010-08-03 |
2012-02-09 |
Beth Israel Deaconess Medical Center |
Procédés et compositions pour le traitement de troubles métaboliques
|
BR112013008100A2
(pt)
|
2010-09-22 |
2016-08-09 |
Arena Pharm Inc |
"moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
JP5728099B2
(ja)
|
2011-02-25 |
2015-06-03 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
抗糖尿病剤として有用な新規環状アザベンゾイミダゾール誘導体
|
DK2686313T3
(en)
|
2011-03-16 |
2016-05-02 |
Probiodrug Ag |
Benzimidazole derivatives as inhibitors of glutaminyl cyclase
|
WO2012135570A1
(fr)
|
2011-04-01 |
2012-10-04 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles qui lui sont associés
|
WO2012145361A1
(fr)
|
2011-04-19 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
|
US20140038889A1
(en)
|
2011-04-22 |
2014-02-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
WO2012145604A1
(fr)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
|
WO2012170702A1
(fr)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
|
US8883800B2
(en)
|
2011-07-15 |
2014-11-11 |
Boehringer Ingelheim International Gmbh |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
WO2013055910A1
(fr)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles associés
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
WO2013171167A1
(fr)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
|
WO2013174767A1
(fr)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
|
US9527875B2
(en)
|
2012-08-02 |
2016-12-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2014074668A1
(fr)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
|
RU2015140066A
(ru)
|
2013-02-22 |
2017-03-30 |
Мерк Шарп И Доум Корп. |
Противодиабетические бициклические соединения
|
WO2014139388A1
(fr)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
|
WO2015051496A1
(fr)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Composés tricycliques antidiabétiques
|
JP6615109B2
(ja)
|
2014-02-28 |
2019-12-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dpp−4阻害薬の医学的使用
|
EA201791982A1
(ru)
|
2015-03-09 |
2020-02-17 |
Интекрин Терапьютикс, Инк. |
Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
|
CN107820496B
(zh)
*
|
2015-07-27 |
2020-11-03 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的新的四环4-氧代-吡啶-3-甲酸衍生物
|
CN105412096A
(zh)
*
|
2015-12-15 |
2016-03-23 |
上海壹志医药科技有限公司 |
药根碱的药物用途
|
EP3468562A1
(fr)
|
2016-06-10 |
2019-04-17 |
Boehringer Ingelheim International GmbH |
Combinaisons de linagliptine et de metformine
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
US10968232B2
(en)
|
2016-12-20 |
2021-04-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
MX2019011867A
(es)
|
2017-04-03 |
2020-01-09 |
Coherus Biosciences Inc |
Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva.
|
DK3461819T3
(da)
|
2017-09-29 |
2020-08-10 |
Probiodrug Ag |
Inhibitorer af glutaminylcyklase
|